Table 3.
Comparison of overall survival in the previous representative studies and in the current study, based on RPA
| RTOG 90-06*60 Gy/30 fr or 72 Gy/60 fr and BCNU | Paravati (2011)** IMRT and TMZ |
Iuchi (2014)*** IMRT (high-dose) and TMZ |
Current study | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | 2-year OS rate (%) | MST (mo) | n | 2-year OS rate (%) | MST (mo) | n | 2-year OS rate (%) | MST (mo) | n | 2-year OS rate (%) | MST (mo) | |
| RPA | ||||||||||||
| III | 105 | 30 | 17.5 | 8 | 67 | 25.0 | 2 | N/A | N/A | 2 | 100 | N/A |
| IV | 240 | 17 | 11.5 | 40 | 31 | 17.7 | 17 | 51 | 25.1 | 9 | 71 | 38.3 |
| V | 150 | 8 | 7.4 | 62 | 12 | 10.8 | 16 | 44 | 21.4 | 12 | 28 | 14.9 |
| VI | 23 | 0 | 2.7 | 17 | 6 | 6.4 | 11 | N/A | N/A | 1 | 0 | 6.5 |
MST = median survival time, mo = months, RTOG = radiation therapy oncology group, RPA = recursive partitioning analysis, BCNU = bis-chlorethyl nitrosourea, TMZ = temozolomide, N/A = not applicable. *Previously reported data from RTOG 90-06 [14]. **Previously reported data from Paravati et al. [15]. ***Previously reported data from Iuchi et al. [2].